Explore Our Biomarker Menu

Biomarker:

HIV-1 Gag p24

Biological or Clinical Significance:

HIV-1 Gag is produced in vast quantities during an infection and is capable of forming virus-like particles in the absence of other viral components. Gag p24, the major capsid protein of the HIV-1 virion, has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different isolates.

It is also well known that HIV infection causes CTL escape mutants of p24, which results in a loss of binding of CTL epitopes either to MHC class I molecules or to the T-cell receptor on CD8+ T cells. Mutations in CTL epitopes and escape from CTL recognition are not unique to HIV and have also been reported for other viruses. However, the effect of impaired antigen processing and presentation of HIV-1 antigens on the generation of CTL escape mutants has not been fully elucidated.

References:

Analyte:

HIV-1 Gag p24

Matrix:

Human Serum

Status:

Experienced Running

Sensitivity-LLOQ:

3.93 pg/mL

Sensitivity-ULOQ:

platform

Ella

Required Sample Volume

Disease State:

MSD Panel:

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.


    Immunogenicity

    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.